Roche pays $775M upfront for Cambridge biotech’s sophomore cancer drug By: Boston Business Journal via Business Journals July 14, 2020 at 10:03 AM EDT A Cambridge biotech is rebounding from an FDA rejection by signing a deal with drug giant Roche worth upwards of $1.7 billion. Read More >>